News
Current news and announcements from Amyloidosis Switzerland
Patient Meeting in Bern – May 15, 2026
March 22, 2026
Amyloidosis Switzerland cordially invites you to a patient meeting in Bern. This meeting provides an opportunity to exchange information among people affected by all types of amyloidosis (ATTR-CM, AL, ATTR-PN and all subtypes).
- Exchange of information and experiences among affected individuals
- Answers to questions about amyloidosis and personal concerns
- Latest therapeutic findings
- Free of charge and no membership required – companions welcome
Registration required – by May 1, 2026
Friday, May 15, 2026, 1:30 PM – 3:00 PM
AMVUTTRA® (Vutrisiran) reimbursed by Swiss health insurance from 1 April 2026
March 1, 2026
From 1 April 2026, AMVUTTRA® (Vutrisiran) is newly reimbursable for the treatment of wild-type or hereditary transthyretin amyloidosis with cardiomyopathy (ATTR-CM).
BEYONTTRA® (Acoramidis) reimbursed by Swiss health insurance from 1 March 2026
February 1, 2026
From 1 March 2026, BEYONTTRA® (Acoramidis) is newly reimbursable for the treatment of wild-type or hereditary transthyretin amyloidosis with cardiomyopathy (ATTR-CM).
Peer to Peer - Affected coaching Affected
January 24, 2025
Martin Bürgi, certified myPeer Coach
Through support at eye level, as an expert from experience, I would like to provide motivating guidance to find a way to deal well with being affected.
- Resource and solution-oriented
- Clear yet flexible
- Open to new ways and ideas
As someone affected by amyloidosis myself, I know the challenges and questions that arise when receiving the diagnosis. I would like to accompany those affected and their relatives in orienting themselves in everyday life after receiving the diagnosis. Support them in finding a path that helps them deal with these challenges.
For this reason, I was able to train as a certified myPeer Coach at the myPeer Association in 2025.
Beyonttra (Acoramidis) approved in Switzerland as of December 18, 2025
December 18, 2025
On December 18, 2025, the Swiss regulatory authority Swissmedic approved the TTR stabilizer Acoramidis for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).
Membership in ProRaris
Since October 2025, the Amyloidosis Switzerland Association has been a member of ProRaris, the umbrella organization for rare diseases in Switzerland. This membership strengthens our position and enables better exchange with other organizations for rare diseases.
Information Event 2025 Video Recording
The video recording of our 2025 information event is now available on YouTube.
Summaries of all presentations available!
In the archive you will find detailed summaries of all presentations from November 15, 2025, including information on cardiac amyloidosis, AL amyloidosis, exercise and movement, and nutrition in amyloidosis.
Online Survey for People with Neurological Diseases - wtATTR Amyloidosis (Wild Type)
The validation of the AmyloScan questionnaire can help patients get an early diagnosis of neuropathies.
- Conducting this research project is not possible without the support of patients.
- Your help is therefore of crucial importance!
- The survey is anonymous and voluntary.
- Participation takes about 30 minutes.